Burosumab (Crysvita®). HTA ID: 23005

Assessment Status Full HTA submission received from Applicant
HTA ID 23005
Drug Burosumab
Brand Crysvita®
Indication Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients.
Assessment Process
Rapid review commissioned 03/02/2023
Rapid review completed 14/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/03/2023
Pre-submission consultation with Applicant 13/06/2023
Full submission received from Applicant 19/09/2023